Sonal Singh1,2, Amit Nautiyal3, Yoon K Loke4. 1. Department of Family Medicine and Community Health, University of Massachusetts School of Medicine, Worcester, Massachusetts, USA. 2. Meyers Primary Care Institute, University of Massachusetts School of Medicine, Worcester, MA, USA. 3. Department of Medicine, Pulmonary and Critical Care Medicine, Albany Medical College, Albany, New York, USA. 4. Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK.
Abstract
BACKGROUND: The influence of direct-acting antiviral (DAA) therapy for chronic hepatitis C virus on the risk of hepatocellular carcinoma (HCC) is conflicting. METHODS: We conducted a systematic review and meta-analysis to determine the incidence or recurrence of HCC associated with oral DAA therapy. We searched PubMed, Scopus, Embase from inception to August 2017 to identify observational studies reporting on HCC among patients treated with DAAs. Two independent reviewers extracted data and assessed the risk of bias. Data were pooled by random-effects model. The primary outcome was the proportion of participants with incidence or recurrence of HCC (PROSPERO number CRD42017057040). RESULTS: After reviewing 2080 citations, we included 8 controlled studies and 36 uncontrolled studies. The pooled proportion for incident HCC was 1.5 % (95% CI 1.0% to 2.1%; I2=90.1%; n= 542/39 145) from 18 uncontrolled studies and 3.3% (95% CI 1.2% to 9%; I2 =96%; n=109/6909) from 5 controlled studies, respectively. The pooled proportion for recurrent HCC was 16.7% (95% CI 10.2% to 26%; I2=84.8%; n=136/867) from 12 uncontrolled studies and 20.1% (95% CI 5.5% to 52.1%; I2=87.5%; n=36/225) from 3 controlled studies, respectively. There was no statistically significant effect on the risk of recurrent HCC (OR 0.50, 95%CI 0.16 to 1.59; I2 =73.4%) in a meta-analysis of three studies. CONCLUSIONS: Our findings show low proportion of incident HCC, but high proportion of recurrent HCC on treatment with DAAs. Continued active surveillance for HCC after treatment with DAAs remains prudent.
BACKGROUND: The influence of direct-acting antiviral (DAA) therapy for chronic hepatitis C virus on the risk of hepatocellular carcinoma (HCC) is conflicting. METHODS: We conducted a systematic review and meta-analysis to determine the incidence or recurrence of HCC associated with oral DAA therapy. We searched PubMed, Scopus, Embase from inception to August 2017 to identify observational studies reporting on HCC among patients treated with DAAs. Two independent reviewers extracted data and assessed the risk of bias. Data were pooled by random-effects model. The primary outcome was the proportion of participants with incidence or recurrence of HCC (PROSPERO number CRD42017057040). RESULTS: After reviewing 2080 citations, we included 8 controlled studies and 36 uncontrolled studies. The pooled proportion for incident HCC was 1.5 % (95% CI 1.0% to 2.1%; I2=90.1%; n= 542/39 145) from 18 uncontrolled studies and 3.3% (95% CI 1.2% to 9%; I2 =96%; n=109/6909) from 5 controlled studies, respectively. The pooled proportion for recurrent HCC was 16.7% (95% CI 10.2% to 26%; I2=84.8%; n=136/867) from 12 uncontrolled studies and 20.1% (95% CI 5.5% to 52.1%; I2=87.5%; n=36/225) from 3 controlled studies, respectively. There was no statistically significant effect on the risk of recurrent HCC (OR 0.50, 95%CI 0.16 to 1.59; I2 =73.4%) in a meta-analysis of three studies. CONCLUSIONS: Our findings show low proportion of incident HCC, but high proportion of recurrent HCC on treatment with DAAs. Continued active surveillance for HCC after treatment with DAAs remains prudent.
Authors: Karin Kozbial; Stephan Moser; Remy Schwarzer; Hermann Laferl; Ramona Al-Zoairy; Rudolf Stauber; Albert F Stättermayer; Sandra Beinhardt; Ivo Graziadei; Clarissa Freissmuth; Andreas Maieron; Michael Gschwantler; Michael Strasser; Markus Peck-Radosalvjevic; Michael Trauner; Harald Hofer; Peter Ferenci Journal: J Hepatol Date: 2016-06-16 Impact factor: 25.083
Authors: Darrick K Li; Yanjie Ren; Daniel S Fierer; Stephanie Rutledge; Obaid S Shaikh; Vincent Lo Re; Tracey Simon; Abdul-Badi Abou-Samra; Raymond T Chung; Adeel A Butt Journal: Hepatology Date: 2018-04-19 Impact factor: 17.425
Authors: G Cabibbo; S Petta; V Calvaruso; I Cacciola; M R Cannavò; S Madonia; M Distefano; L Larocca; T Prestileo; F Tinè; G Bertino; L Giannitrapani; F Benanti; A Licata; I Scalisi; G Mazzola; F Cartabellotta; N Alessi; M Barbàra; M Russello; G Scifo; G Squadrito; G Raimondo; A Craxì; V Di Marco; C Cammà Journal: Aliment Pharmacol Ther Date: 2017-08-09 Impact factor: 8.171
Authors: H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki Journal: N Engl J Med Date: 1993-06-24 Impact factor: 91.245
Authors: Graham R Foster; William L Irving; Michelle C M Cheung; Alex J Walker; Benjamin E Hudson; Suman Verma; John McLauchlan; David J Mutimer; Ashley Brown; William T H Gelson; Douglas C MacDonald; Kosh Agarwal Journal: J Hepatol Date: 2016-01-30 Impact factor: 30.083
Authors: Iman Ibrahim Salama; Hala M Raslan; Ghada A Abdel-Latif; Somaia I Salama; Samia M Sami; Fatma A Shaaban; Aida M Abdelmohsen; Walaa A Fouad Journal: World J Hepatol Date: 2022-06-27
Authors: Muhammad Atif; Muhammad Abdul Mustaan; Sadia Falak; Abdul Ghaffar; Bushra Munir Journal: Saudi J Biol Sci Date: 2022-06-01 Impact factor: 4.052
Authors: Byung Soo Kwan; Jeong Han Kim; Seong Jun Park; Won Hyeok Choe; So Young Kwon; Byung-Chul Yoo Journal: Korean J Intern Med Date: 2020-04-03 Impact factor: 2.884
Authors: Fatih Karbeyaz; Seraphina Kissling; Paul Julius Jaklin; Jaqueline Bachofner; Barbara Brunner; Beat Müllhaupt; Thomas Winder; Joachim C Mertens; Benjamin Misselwitz; Stefanie von Felten; Alexander R Siebenhüner Journal: J Hepatocell Carcinoma Date: 2021-06-11